Human cancer studies on exposure to PCP: Differentiating potential cancer effects of PCP exposure from effects due to occupational co-exposures or PCP contaminants
Process for Preparation of the Report on Carcinogens (RoC)

1. **Nomination and Selection of Candidate Substances**
   - Invite nominations to the RoC
   - Interagency review
   - Public comment
   - Develop draft concept documents for substances proposed for evaluation
   - Public comment
   - Review of draft concept documents by NTP Board of Scientific Counselors*
     (public meeting, public comment)
   - NTP Director
   - Select candidate substances

2. **Scientific Evaluation of Candidate Substances**
   - Prepare draft RoC Monograph for a candidate substance
     (initiate cancer evaluation component)
   - External scientific input, as needed
     (e.g., consultants, ad hoc presentations, expert panels*)
   - Public input
     (e.g., listening session, comment)
   - Interagency input
     (complete cancer evaluation component and prepare draft substance profile)
   - Interagency review
   - Complete draft RoC Monograph

3. **Public Release and Peer Review of Draft RoC Monographs**
   - Release draft RoC Monograph
   - Public comment
   - Peer review of draft RoC Monograph by NTP Peer-Review Panel*
     (public meeting, public comment, peer-review report)
   - Present information regarding the peer review and revised draft RoC Monograph to NTP Board of Scientific Counselors (BSC)
     (public meeting, public comment)
   - NTP Director
   - Finalize RoC Monograph
     (cancer evaluation component and substance profile)

   - Submit recommended listing status for newly reviewed candidate substances
   - NTP Executive Committee
   - Approval of listing status by Secretary, HHS
     (transmit latest edition of RoC to Congress and release to the public)

* Federally chartered advisory groups

**Key**
- HHS = Health and Human Services
- NTP = National Toxicology Program
Selection of PCP as a Candidate Substance

- Sodium salt primarily used as a wood preservative in the United States.
- Selected as a candidate substance based on widespread past use and current U.S. exposure and an adequate database of studies in humans and animals.

http://ntp.niehs.nih.gov/go/37897
Scientific Review of PCP: PCP Webinar

Objective

- Provide scientific input to the Office of the RoC (ORoC) on issues related to its approach for evaluating the epidemiologic studies on exposure to PCP
- Not to receive recommendations from invited speakers or the public on whether or not PCP should be listed in the RoC

http://ntp.niehs.nih.gov/go/pcpwebinar
# Webinar Agenda

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and Introduction</td>
<td>Dr. Ruth Lunn, ORoC, NIEHS</td>
</tr>
<tr>
<td>Webinar Logistics</td>
<td>Dr. Glinda Cooper (U.S. EPA); Moderator</td>
</tr>
<tr>
<td><strong>Seminar Presentations</strong></td>
<td></td>
</tr>
<tr>
<td>Overview of occupational exposures to pentachlorophenol: Components, contaminants, and common co-exposures</td>
<td>Mr. Kevin Dunn, National Institute for Occupational Safety and Health (NIOSH)</td>
</tr>
<tr>
<td>Occupational exposure to PCP and other agents: Issues to consider in evaluating human epidemiology studies</td>
<td>Dr. Avima Ruder, NIOSH</td>
</tr>
<tr>
<td>Biomonitoring and epidemiologic studies of PCP producers</td>
<td>Dr. Jim Collins, The Dow Chemical Company</td>
</tr>
<tr>
<td>Epidemiologic studies of PCP users</td>
<td>Dr. Paul Demers, Occupational Cancer Research Centre, Cancer Care Ontario</td>
</tr>
<tr>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>Panel-initiated questions</td>
<td>Drs. Cooper and Mary Schubauer-Berigan (NIOSH)</td>
</tr>
<tr>
<td>Public-initiated questions</td>
<td></td>
</tr>
<tr>
<td><strong>Closing Remarks</strong></td>
<td>Dr. Cooper</td>
</tr>
</tbody>
</table>
Webinar Logistics: Public Participation

• Opportunities for public participation
  – Question and answer period following each presentation
  – General discussion: panel-initiated questions/topics (discussion leader, moderator, speaker, or NTP staff)
    • Questions should be related to the topics initiated by the panel
    • The moderator will indicate when questions will be received from the public
  – General discussion: public-initiated questions/topics
    • Questions/comments can be on any topic related to the webinar

• Methods for asking a question or making a comment
  – Oral comment using your phone line: Use the “Raise your hand” in Adobe Connect and wait for the moderator to acknowledge you.
  – Write your comment/question in the question and answer box: The moderator will read your comment/question aloud.

Technical assistance: Chat box or email Diane Spencer at spencer2@niehs.nih.gov
Webinar Logistics: Virtual Meeting Room

- Panel is at four virtual locations
- NIOSH location
  - Speakers: Avima Ruder, Kevin Dunn
  - Discussion leader: Mary Schubauer-Berigan
- NIEHS location
  - ORoC or contract staff: Ruth Lunn, Gloria Jahnke, Jennie Ratcliffe, Diane Spencer
  - NTP: John Bucher, Mary Wolfe, Nigel Walker
  - Moderator: Glinda Cooper
- In general, the panel-initiated discussion will start with NIOSH, proceed clockwise around the "virtual table", and then move to the audience.

*Starting and focal point of the discussion